Scholarlink

<p>Leucine-rich alpha-2 glycoprotein 1 (LRG1) is an extracellular protein whose elevated expression has been linked to cancers with poor prognosis and low survival rates. Given its significance as a biomarker, this manuscript explores the role of LRG1 in cancer, as several studies have identified it as a promoter of proliferation, angiogenesis, invasion, and metastasis in breast, ovarian, pancreatic, and neuroblastoma cancers. However, contrasting evidence suggests that LRG1 inhibits proliferation in hepatocellular carcinoma cells and suppresses migration and invasion in esophageal squamous cell carcinoma. We also examine its regulation and the associated signaling pathways, including TGF-β and PI3K/AKT/mTOR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LRG1 in cancer: mechanisms, potential therapeutic target, and use in clinical diagnosis

  • 期刊论文

  • 发表日期：

    2025年6月10日

查看全文
  • Federico Osorio-Antonio,
  • Daniela Michel Diaz-González,
  • Elizabeth Bautista-Rodríguez,
  • Gabriela Elizabeth Campos-Viguri,
  • Oscar Peralta-Zaragoza,
  • José Manuel Sánchez-López,
  • José Luis Cortez-Sánchez,
  • Cristina Muñoz-Olivos,
  • Francisco Castelán,
  • Verónica Velázquez-Orozco

摘要

Leucine-rich alpha-2 glycoprotein 1 (LRG1) is an extracellular protein whose elevated expression has been linked to cancers with poor prognosis and low survival rates. Given its significance as a biomarker, this manuscript explores the role of LRG1 in cancer, as several studies have identified it as a promoter of proliferation, angiogenesis, invasion, and metastasis in breast, ovarian, pancreatic, and neuroblastoma cancers. However, contrasting evidence suggests that LRG1 inhibits proliferation in hepatocellular carcinoma cells and suppresses migration and invasion in esophageal squamous cell carcinoma. We also examine its regulation and the associated signaling pathways, including TGF-β and PI3K/AKT/mTOR.